Showing results (51-60 of 259) with videos related to
Sort By:
Pageof 26
British Journal of Haematology|May 14, 2011
Attainment of complete/very good partial response following rituximab-based therapy is an important determinant to progression-free survival, and is impacted by polymorphisms in FCGR3A in Waldenstrom macroglobulinaemiaSteven P Treon, Guang Yang, Christine Hanzis, et al.Expert Review of Hematology|January 11, 2014
Waldenström macroglobulinemia: from biology to treatmentIlyas Sahin, Houry Leblebjian, Steven P Treon, et al.Blood|July 10, 2013
A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenström macroglobulinemiaGuang Yang, Yangsheng Zhou, Xia Liu, et al.International Journal of Cancer|December 19, 2022
Dysfunctions of innate and adaptive immune tumor microenvironment in Waldenström macroglobulinemiaDanka Cholujova, Gabor Beke, Zachary R Hunter, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 10, 2008
Increased incidence of transformation and myelodysplasia/acute leukemia in patients with Waldenström macroglobulinemia treated with nucleoside analogsXavier Leleu, Jacob Soumerai, Aldo Roccaro, et al.Therapeutic Advances in Hematology|August 6, 2016
Ibrutinib in Waldenström macroglobulinemia: latest evidence and clinical experienceJorge J Castillo, M Lia Palomba, Ranjana Advani, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 2005
Diagnosis and management of Waldenstrom's macroglobulinemiaMeletios A Dimopoulos, Robert A Kyle, Athanasios Anagnostopoulos, et al.Leukemia & Lymphoma|February 11, 2021
Clinical application of genomics in Waldenström macroglobulinemiaAndrew R Branagan, Mathew Lei, Steven P Treon, et al.Seminars in Oncology|April 30, 2003
Proteomic analyses in Waldenstrom's macroglobulinemia and other plasma cell dyscrasiasConstantine S Mitsiades, Nicholas Mitsiades, Steven P Treon, et al.Clinical Lymphoma & Myeloma|February 28, 2007
Genetic linkage of Fc gamma RIIa and Fc gamma RIIIa and implications for their use in predicting clinical responses to CD20-directed monoclonal antibody therapyEvdoxia Hatjiharissi, Mark Hansen, Daniel Ditzel Santos, et al.Pageof 26